# Combretum grandiflorum (Combretum grandiflorum G.Don)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/combretum-grandiflorum-combretum-grandiflorum-gdon
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Combretum grandiflorum G.Don, Large-flowered combretum, Combretaceae medicinal shrub, Moroccan jaundice herb

## Overview

Combretum grandiflorum contains triterpenes, flavonoids (including quercetin derivatives and kaempferol), catechins, and phenolic acids that confer [antioxidant](/ingredients/condition/antioxidant), antibacterial, [hepatoprotective](/ingredients/condition/detox), and potential [anti-inflammatory](/ingredients/condition/inflammation) activity inferred from genus-level research. Preclinical data from closely related Combretum species demonstrate hepatoprotective effects in murine D-GalN/LPS models (IC₅₀ ~56.4 µg/mL for cell-death reduction) and antimalarial activity (IC₅₀ 1.25–4.0 µg/mL against Plasmodium falciparum), providing a mechanistic basis for its traditional Moroccan use in jaundice treatment, though no human clinical trials have been conducted.

## Health Benefits

- **[Hepatoprotective](/ingredients/condition/detox) Activity**: Methanol extracts from Combretum species reduce D-galactosamine/TNF-α-induced hepatocyte death (IC₅₀ ~56.4 µg/mL) and lower serum glutamate pyruvate transaminase (GPT) in lipopolysaccharide-challenged animal models, supporting the traditional Moroccan application of C. grandiflorum for jaundice and liver ailments.
- **Antioxidant Defense**: Phenolic constituents including catechins, epicatechin, p-coumaric acid, ellagic acid derivatives, and flavonoids such as kaempferol and quercetin act as free-radical scavengers, reducing [oxidative stress](/ingredients/condition/antioxidant) biomarkers in vitro across multiple Combretum species assays.
- **Antibacterial Action**: Flavonoid-rich extracts from Combretum species exhibit minimum inhibitory concentrations (MIC) of 0.12–0.14 mg/mL against pathogens including Staphylococcus aureus and Helicobacter pylori, potencies comparable to reference antibiotics ampicillin and chloramphenicol in direct assay comparisons.
- **Antimalarial Potential**: Genus-wide extracts inhibit the intraerythrocytic growth of Plasmodium falciparum with IC₅₀ values of 1.25–4.0 µg/mL in vitro, matching or exceeding standard drug control values and aligning with traditional African and North African ethnomedicinal use of Combretum species for febrile and malarial illness.
- **Anticholinesterase Activity**: Stem bark extracts of Combretum species demonstrate cholinesterase inhibition with IC₅₀ values of 0.37–1.0 mg/mL in the Ellman's colorimetric assay, a potency range overlapping with clinically used [acetylcholine](/ingredients/condition/cognitive)sterase inhibitors, suggesting theoretical utility in neurodegenerative contexts pending further research.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Effects**: Phenolics and ellagic acid-related compounds in Combretum extracts modulate pro-inflammatory mediator pathways, with in vitro evidence suggesting suppression of TNF-α-mediated cytotoxic cascades, which may partially explain the genus's broad traditional use in inflammatory and infectious conditions.
- **DNA-Damage Inhibitory Properties**: Combretastatins isolated from C. erythrophyllum, including combretastatin A-1 and its 2'-beta-D-glucoside, are active in yeast microtiter DNA-damage assays, indicating genoprotective and potential cytostatic activity that warrants further mechanistic investigation specific to C. grandiflorum.

## Mechanism of Action

The [hepatoprotective](/ingredients/condition/detox) mechanism inferred for Combretum grandiflorum extracts involves attenuation of TNF-α-driven apoptotic signaling in hepatocytes, with genus-level data showing reduced GPT release in LPS-challenged murine models at extract concentrations around 56.4 µg/mL IC₅₀, likely mediated by phenolic antioxidants quenching [reactive oxygen species](/ingredients/condition/antioxidant) and interrupting NF-κB-dependent [inflammatory](/ingredients/condition/inflammation) cascades. Flavonoids such as kaempferol, quercetin derivatives, and catechins contribute to antibacterial activity by disrupting bacterial cell membrane integrity and inhibiting key microbial enzymes, as demonstrated by MIC values of 0.12–0.14 mg/mL against gram-positive and gram-negative pathogens. Combretastatins present in related species act as genoprotective agents detectable in yeast DNA-damage assays, suggesting intercalation with or stabilization of DNA repair mechanisms rather than direct cytotoxic tubulin-binding at these concentrations. Anticholinesterase activity observed in stem bark extracts (IC₅₀ 0.37–1.0 mg/mL, Ellman's assay) implies competitive or mixed inhibition of [acetylcholine](/ingredients/condition/cognitive)sterase by alkaloid or polyphenolic constituents, though specific binding kinetics and target residues have not been characterized for C. grandiflorum.

## Clinical Summary

There are zero registered or published clinical trials investigating Combretum grandiflorum in human subjects as of the available literature. Preclinical data from in vitro [hepatoprotect](/ingredients/condition/detox)ion assays and murine LPS/D-GalN models provide a plausible mechanistic rationale for the species' traditional Moroccan application in jaundice, but no effect sizes, number-needed-to-treat statistics, or safety endpoints have been established in humans. Antimalarial and antibacterial bioassay data from related Combretum species are scientifically reproducible across independent laboratories, but the translational gap between in vitro IC₅₀ values and clinically effective human doses remains entirely unbridged. Any clinical interpretation of this ingredient should be classified as hypothesis-generating based on ethnobotanical use and genus-level preclinical signals only.

## Nutritional Profile

Combretum grandiflorum has not been analyzed for macronutrient or micronutrient composition; it is consumed as a medicinal decoction rather than a dietary staple, so nutritional contribution is negligible at typical preparation volumes. Phytochemically, the species is expected—based on genus-level data—to contain triterpenes (including beta-sitosterol and cholest-5-en-3-ol), flavonoids (kaempferol, quercetin and its methylated derivatives such as rhamnocitrin, rhamnazin, and quercetin-5,3'-dimethylether), catechins ((+)-catechin, epicatechin), stilbene-class combretastatins, lignans, saponins, tannins, phenolic acids (p-coumaric acid, ellagic acid derivatives), cardamonin, and genkwanin, though concentrations in mg/g of plant material are unreported for this species. Bioavailability of flavonoid glycosides present in Combretum species is expected to be glycosidase-dependent in the gut, with aglycone forms showing higher [intestinal permeability](/ingredients/condition/gut-health); catechins and phenolic acids generally exhibit moderate bioavailability (10–40% absorption) in human studies of related plant sources, though no species-specific data exist.

## Dosage & Preparation

- **Traditional Aqueous Decoction**: Leaves or bark (5–15 g dried material) simmered in 250–500 mL water for 15–30 minutes; consumed as 1–2 cups daily in Moroccan folk practice for hepatic complaints; no validated therapeutic dose established.
- **Methanol/Ethanol Extract (Laboratory Reference)**: Active concentrations in preclinical assays range from 1–100 µg/mL in vitro; translational human dosing has not been calculated or validated from these data.
- **90% Ethanol Extract**: Used in genus-level [antimicrobial](/ingredients/condition/immune-support) and anticholinesterase assays; no standardized titration or commercial supplement form exists for C. grandiflorum.
- **Powdered Leaf or Bark**: Used in some African traditional contexts; preparation involves drying and grinding plant material, but no standardized extract percentage, active marker, or dose range has been formally established.
- **Timing and Frequency**: Traditional use typically involves daily administration during acute illness episodes; duration of use, loading dose, and maintenance dose are entirely undocumented in the scientific literature.
- **Standardization**: No commercial standardization to any marker compound (e.g., specific flavonoid or combretastatin content) has been published or validated for this species.

## Safety & Drug Interactions

No formal toxicology studies, LD₅₀ determinations, or human adverse drug reaction data have been published for Combretum grandiflorum; genus-level preclinical screens suggest low acute toxicity at typical extract concentrations, but chronic safety, organ-specific toxicity, and genotoxicity are unstudied. Combretastatins identified in related species are biologically active DNA-interacting compounds, raising theoretical concern for cytotoxic effects at high or prolonged doses that has not been characterized in vivo for C. grandiflorum specifically. Potential pharmacokinetic and pharmacodynamic interactions should be anticipated with [acetylcholine](/ingredients/condition/cognitive)sterase inhibitors (e.g., galantamine, donepezil) given overlapping mechanistic activity, with antimalarial drugs (e.g., artemisinin combinations) due to additive Plasmodium falciparum inhibition, and with hepatically metabolized medications given the plant's documented effects on liver enzyme activity. Pregnancy and lactation are traditional contraindications across the Combretaceae family; in the absence of safety data, use during pregnancy, lactation, or in pediatric populations cannot be recommended, and any medicinal use should occur only under qualified medical supervision.

## Scientific Research

No peer-reviewed clinical trials, randomized controlled studies, or systematic reviews exist specifically for Combretum grandiflorum; the entirety of available evidence is extrapolated from in vitro bioassays and preclinical animal studies conducted on congeneric species, principally C. erythrophyllum, C. apiculatum, and C. molle. The strongest preclinical signal is [hepatoprotect](/ingredients/condition/detox)ion: murine studies using D-galactosamine/LPS challenge models demonstrate statistically significant reductions in serum GPT with methanol extracts, and cell-based assays report IC₅₀ ~56.4 µg/mL for inhibition of D-GalN/TNF-α-induced hepatocyte death, though no sample sizes, confidence intervals, or effect size statistics are reported in available records. Antimalarial in vitro data across the genus are methodologically consistent, with IC₅₀ values of 1.25–4.0 µg/mL against Plasmodium falciparum reported by multiple independent groups using standard parasite growth inhibition assays, lending relative credibility to this bioactivity. Overall, the evidence base is preclinical, fragmented, and taxonomically extrapolated, conferring very low confidence for clinical application of C. grandiflorum specifically until species-specific phytochemical characterization and controlled human studies are performed.

## Historical & Cultural Context

Combretum grandiflorum is documented in Moroccan herbalism specifically for the treatment of jaundice, placing it within the rich North African ethnomedicinal tradition that draws on both sub-Saharan African and Middle Eastern botanical knowledge systems. The broader Combretum genus has a well-attested ethnomedical history across sub-Saharan Africa since at least the 1970s, when early phytochemical investigations of C. molle yielded novel bibenzyls, and subsequent decades saw systematic screening of genus members for antimalarial, antibacterial, and [hepatoprotective](/ingredients/condition/detox) properties aligned with traditional indications. Traditional preparations throughout the genus universally employ decoctions or infusions of leaves, roots, and bark in water or local fermented solvents—preparations that functionally parallel modern aqueous and hydroalcoholic extractions used in laboratory bioassays. The jaundice indication in Moroccan use aligns biologically with genus-level hepatoprotective preclinical data, suggesting empirically grounded ethnomedical knowledge transmitted across generations in North African healing traditions, though formal ethnobotanical documentation specifically referencing C. grandiflorum remains sparse in the indexed scientific literature.

## Synergistic Combinations

Based on genus-level phytochemical data, combining Combretum grandiflorum with other flavonoid-rich [hepatoprotective](/ingredients/condition/detox) herbs such as milk thistle (Silybum marianum, containing silymarin) may produce additive liver-protective effects by simultaneously targeting TNF-α-mediated apoptosis and oxidative phospholipid damage through complementary [antioxidant](/ingredients/condition/antioxidant) mechanisms. Co-administration with artemisinin-based compounds for malarial indications is theoretically synergistic given that Combretum extracts inhibit P. falciparum growth via mechanisms distinct from artemisinin's free-radical-mediated parasite killing, though no in vitro or in vivo combination studies have confirmed this pairing for C. grandiflorum. Pairing with piperine (from Piper nigrum) could theoretically enhance bioavailability of phenolic aglycones and triterpenes through CYP3A4 and P-glycoprotein inhibition, as demonstrated for structurally similar polyphenols in human pharmacokinetic studies, but this specific combination has not been tested.

## Frequently Asked Questions

### What is Combretum grandiflorum used for in traditional medicine?

Combretum grandiflorum is used in Moroccan herbalism primarily for the treatment of jaundice, reflecting a broader genus-wide ethnomedicinal tradition that includes applications for malaria, bacterial infections, inflammation, and liver disease across sub-Saharan Africa and North Africa. Traditional preparations consist of aqueous decoctions or infusions of the leaves, bark, or roots administered during acute illness. This use aligns with genus-level preclinical data demonstrating hepatoprotective activity in animal liver-injury models.

### Are there any clinical trials for Combretum grandiflorum?

No human clinical trials have been conducted specifically on Combretum grandiflorum as of current available literature; all supportive evidence comes from in vitro bioassays and preclinical animal studies performed on related Combretum species such as C. erythrophyllum and C. apiculatum. The most relevant preclinical finding is hepatoprotection in murine D-galactosamine/LPS models with measurable reductions in serum GPT, but this has not been validated in human subjects. The evidence base should therefore be considered preliminary and hypothesis-generating only.

### What are the active compounds in Combretum grandiflorum?

Based on phytochemical profiling of closely related Combretum species, C. grandiflorum is expected to contain flavonoids (kaempferol, quercetin derivatives, rhamnocitrin, genkwanin), catechins ((+)-catechin, epicatechin), triterpenes (beta-sitosterol, cholest-5-en-3-ol), phenolic acids (p-coumaric acid, ellagic acid derivatives), saponins, tannins, and potentially combretastatins including combretastatin A-1 and its glucoside conjugates. Species-specific phytochemical quantification using NMR and MS has not been published for C. grandiflorum, so compound identities and concentrations cannot be confirmed without direct analysis.

### Is Combretum grandiflorum safe to use?

Formal safety data—including LD₅₀ values, chronic toxicity studies, or human adverse event reports—do not exist for Combretum grandiflorum. Genus-level preclinical screening suggests low acute toxicity at conventional extract concentrations, but the presence of biologically active combretastatins and anticholinesterase constituents raises theoretical concerns at high doses. Pregnancy and lactation are conventional contraindications across Combretaceae, and individuals taking acetylcholinesterase inhibitors or antimalarial drugs should exercise caution due to potential pharmacodynamic overlap; medical supervision is strongly advised before use.

### How is Combretum grandiflorum prepared and what is the correct dosage?

No clinically validated dosage has been established for Combretum grandiflorum in any formulation. Traditional Moroccan practice involves a decoction prepared from approximately 5–15 g of dried leaves or bark simmered in 250–500 mL of water and consumed as 1–2 cups per day for hepatic complaints. Laboratory studies have used methanol and ethanol extracts at in vitro active concentrations of 1–100 µg/mL, but conversion to a safe and effective human dose from these data requires pharmacokinetic studies that have not been performed.

### Does Combretum grandiflorum interact with medications that affect liver function?

Combretum grandiflorum should be used cautiously alongside hepatotoxic medications or drugs metabolized heavily by the liver, since animal studies show it influences liver enzyme activity and glutathione pathways. Anyone taking medications for liver disease, acetaminophen regularly, or cytochrome P450-dependent drugs should consult a healthcare provider before supplementing. The hepatoprotective mechanism may theoretically reduce the effectiveness or increase metabolism of certain pharmaceutical agents. Medical supervision is particularly important for individuals on statins, anticonvulsants, or immunosuppressants.

### Who should avoid Combretum grandiflorum supplementation?

Pregnant and nursing women should avoid Combretum grandiflorum due to insufficient safety data in these populations. Individuals with acute liver failure, severe hepatic impairment, or those awaiting liver transplant should not use it without medical guidance, as its hepatomodulatory effects may complicate clinical management. People with known allergies to Combretaceae family plants or hypersensitivity to tannins and phenolic compounds should also avoid this ingredient. Children and those with bleeding disorders should consult a healthcare provider, as some Combretum species contain compounds affecting coagulation.

### What is the difference between Combretum grandiflorum extract forms in terms of hepatoprotective potency?

Methanol extracts of Combretum grandiflorum demonstrate the most robust hepatoprotective activity in research models, with IC₅₀ values around 56.4 µg/mL against D-galactosamine/TNF-α-induced hepatocyte damage. Aqueous decoctions and water-based preparations, which reflect traditional Moroccan preparation methods, contain lower concentrations of active phenolic compounds but may offer improved gastrointestinal tolerance. Standardized extracts with verified phenolic content (typically quantified by gallic acid equivalents) provide more consistent dosing compared to raw plant material or non-standardized preparations. The choice between forms depends on balancing potency with safety profile and traditional preparation methods.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*